A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)

Administered By

Awarded By

Contributors

Start/End

  • May 10, 2021 - May 14, 2026